Refeeding syndrome
Refeeding syndrome (RFS) is a potentially serious metabolic condition that can arise when nutrition is reintroduced to severely malnourished individuals. This syndrome is characterized by an imbalance of water-electrolytes, glucose intolerance, cardiac arrhythmias, and diarrhea, typically occurring within the first five days of refeeding.[1]
Understanding Refeeding Syndrome[edit | edit source]
The hallmark of refeeding syndrome is a shift in fluids and electrolytes in a malnourished individual who receives nutritional supplementation. This shift can lead to severe complications such as heart failure, respiratory failure, and death if not recognized and managed promptly.
Causes and Risk Factors[edit | edit source]
The primary cause of RFS is the reintroduction of glucose, or carbohydrates, to a severely malnourished individual. Risk factors include prolonged fasting, low BMI, significant unintentional weight loss, and underlying chronic diseases such as cancer and chronic gastrointestinal diseases.[2]
Symptoms[edit | edit source]
Symptoms of RFS can vary widely and may include fatigue, muscle weakness, seizures, heart failure, and even coma.
Diagnosis[edit | edit source]
The diagnosis of RFS is often clinical, made by observing the patient's response to nutritional reintroduction. However, blood tests are essential to monitor electrolyte levels, especially phosphorus, magnesium, and calcium.[3]
Management[edit | edit source]
Management of RFS requires careful monitoring and correction of electrolyte imbalances, along with gradual, controlled reintroduction of nutrients. In some cases, intravenous electrolyte replacement may be necessary.[4]
See Also[edit | edit source]
Refeeding syndrome Resources | ||
---|---|---|
|
|
- ↑
- ↑
- ↑ "Refeeding Syndrome". UpToDate. Retrieved 2023-05-18.
- ↑
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD